u/zaid_grimaldi

Bought small deliberately because the evidence base is thin. That felt like the only defensible approach.

Same. Perimenopause overlapping with all of this is the least documented area on the whole site.

Hormonal variation across the cycle affects appetite, fluid retention and subjective symptom intensity independently of anything else, which is why an unannotated log can look mysterious.

Correction: that is the combination programme, not the monotherapy readout. Different arms, different numbers.

I would not extrapolate the tolerability profile from the monotherapy arm to the combination. The trials report them separately for a reason.

Disagree — a 503B being registered does not make its preparations equivalent to an approved product. Different regulatory category entirely.

The same dose genuinely feels different at different points in the month for me. Took a year to notice and it was in the log the whole time.

Nothing here is medical or legal advice. The pharmacist and the prescriber are the people who can act, and both are faster than a forum.

That figure is the starting material purity, not the finished preparation potency. Two different tests.

Same view. If the intake asked you nothing, the intake was a formality and you should factor that in.

nothing here is approved as a standalone product and research material is not for human use

Body weight varies by a couple of kilos day to day through fluid, glycogen and gut content, which is why a single weigh-in is noise and a fortnightly trend is signal.

Switched between two compounded preparations and the concentration on the label was different. Redid the arithmetic on paper before drawing anything.

That is a waist measurement, not a weight, and the thread has been comparing them as though they were the same.

the pharmacy and the prescriber are two separate questions

This. Waist measurement kept moving through my longest stall and it was the only thing that kept me sane.

Agreed on keeping every form and date. When something goes wrong the paper trail is the whole case.

Quantity limits restrict how much may be dispensed in a period even where coverage exists. They are a distinct barrier and require a distinct request.

the first person to notice was me, months after it started

Agreed — measurements over photographs, every time, for anybody trying to actually track something.

503A is patient-specific, 503B is outsourcing facility, they are not the same thing

The three separate questions people ask here as though they were one.

Agreed — write the application against the published criteria rather than around them.

Potency and sterility testing on the finished preparation are separate from any certificate covering the starting material. Ask which you are being shown.

Salt form matters for mass: a preparation specified as one salt and dosed as the free base gives you a different amount of peptide for the same number on the label.

Yes. The shortage list is the legal hinge for the whole arrangement and its status is public.

National regulatory approval establishes that a product may be sold. Whether any plan pays for it is a separate decision, and public drug plans are administered provincially.

Not convinced. A rejected claim at the counter is not a denied authorization and the next step differs.

Published reimbursement criteria exist in most member states and are usually available in the national language. They are the authoritative answer to eligibility questions that this board can only guess at.

Which trial and which readout?

cycle timing changes how the same week feels

santiago_marchetti is right that a diagnosis and a finding are different things here.

Dosing intuitions from the GLP-1 boards do not transfer. Different receptor family, different exposure-response, and no published schedule for members to reason from.

Compounded preparations are not approved products and carry no bioequivalence claim. That is a statement about regulatory category, not about quality.

What is the beyond-use date and what is it based on?

keep every form, every date, every reference number

Small fix — those two prices are for different pack sizes, which accounts for most of the gap.

I would not read one person’s cycle-linked experience as a general pattern. The variation here is enormous.

Independent purity data on this compound is sparse compared with the older molecules, simply because far fewer members have paid for testing. Sparse data means wide uncertainty, not a verdict.

Correction: that is the authorisation position, and the question was about reimbursement. Different bodies, different answers.

keep every form, every date, every reference number

the middle is the part nobody posts and everybody lives in

the API source is the question nobody asks and everybody should